Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone
August 01, 2024 09:00 ET
|
PRISM Mediawire
Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
July 15, 2024 10:16 ET
|
PRISM MarketView
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
June 05, 2024 08:00 ET
|
PRISM MarketView
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
May 21, 2024 12:35 ET
|
PRISM MarketView
PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
UPDATE: New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets
October 17, 2022 10:16 ET
|
FMW Media Works Corp
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- FMW Media Inc.'s New to The Street is pleased to announce that Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on...
New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets
October 17, 2022 08:30 ET
|
FMW Media Works Corp
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- FMW Media Inc.'s New to The Street is pleased to announce that Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on...